VX-993
- Generic Name
- VX-993
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 355
- Registration Number
- NCT06619847
- Locations
- 🇺🇸
Shoals Medical Trials Inc., Sheffield, Alabama, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 300
- Registration Number
- NCT06619860
- Locations
- 🇺🇸
Health Awareness, Inc., Jupiter, Jupiter, Florida, United States
🇺🇸Suncoast Research Associates - Miami, Miami, Florida, United States
🇺🇸Eximia Research - Raleigh, Raleigh, North Carolina, United States
Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT06523595
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06508762
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 92
- Registration Number
- NCT06420765
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 88
- Registration Number
- NCT06394167
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
- Conditions
- Pain
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT06226454
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT05653323
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.